arrow
K

Kei Endo

iwate medical university
H指数:26
被引数:1,911

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

阿特珠单抗联合贝伐珠单抗治疗巴塞罗那临床肝细胞癌B2期患者的疗效

2026-09-290
OAAI
Competing risks of treatment discontinuation of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma

不可切除性肝细胞癌中阿替利珠单抗联合贝伐珠单抗治疗中断的竞争风险

2026-08-110
OAAI
Myeloperoxidase-anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis
2025-10-010
PRE
Autoimmune hepatitis following transition from prednisolone to thrombopoietin receptor agonist therapy in immune thrombocytopenic purpura: A clinical precaution

从泼尼松转换为促血小板生成素受体激动剂治疗特发性血小板减少性紫癜后发生自身免疫性肝炎:一项临床注意事项

2025-04-180
PRE
Optimizing Cabozantinib Dosing in Unresectable Hepatocellular Carcinoma of 7-on/7-off Regimen

优化7-on/7-off方案下不可切除肝细胞癌的卡博赞替尼剂量

CANCERS
IF4.4
2025-04-100
OA
Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study
2025-02-180
OAAI
Impact of shear wave elastography and attenuation imaging for predicting life-threatening event in patients with metabolic dysfunction-associated steatotic liver disease
2025-02-070
OAAI
Coincidental items in the definition of metabolic dysfunction-associated fatty liver are useful in identifying patients having significant fibrosis with fatty liver

代谢功能障碍相关脂肪肝定义中的巧合项可用于识别患有脂肪肝的显着纤维化患者

2023-06-152
PRE
Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis

针对血液科接受碳青霉烯治疗的患者的抗菌药物管理计划: 单中心和中断时间序列分析

2023-02-021
OA